Petros Pharmaceuticals, Inc.: basic weighted-average shares
Basic weighted-average shares for Petros Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Petros Pharmaceuticals, Inc. financial histories
What this measure means
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Reading these values
This selected numerical history matches Diluted weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 28,065,362 | shares | 2026-04-15 | 10-K · 0001104659-26-043822 |
| 2024-01-01 | 2024-12-31 | 321,042 | shares | 2026-04-15 | 10-K · 0001104659-26-043822 |
| 2023-01-01 | 2023-12-31 | 2,176,017 | shares | 2025-03-31 | 10-K · 0001410578-25-000579 |
| 2022-01-01 | 2022-12-31 | 2,070,210 | shares | 2024-04-01 | 10-K · 0001410578-24-000401 |
| 2021-01-01 | 2021-12-31 | 1,088,977 | shares | 2023-03-31 | 10-K · 0001410578-23-000575 |
| 2020-01-01 | 2020-12-31 | 5,340,682 | shares | 2022-03-31 | 10-K · 0001410578-22-000783 |
Related financial histories
- Petros Pharmaceuticals, Inc.: total assets
- Petros Pharmaceuticals, Inc.: total liabilities
- Petros Pharmaceuticals, Inc.: stockholders equity
- Petros Pharmaceuticals, Inc.: cash and cash equivalents
- Petros Pharmaceuticals, Inc.: net income or loss
- Petros Pharmaceuticals, Inc.: operating cash flow
- Petros Pharmaceuticals, Inc.: contract revenue excluding tax
- Petros Pharmaceuticals, Inc.: financing cash flow
- Petros Pharmaceuticals, Inc.: retained earnings or deficit
- Petros Pharmaceuticals, Inc.: diluted weighted-average shares
- Petros Pharmaceuticals, Inc.: basic earnings per share
- Petros Pharmaceuticals, Inc.: diluted earnings per share
- Petros Pharmaceuticals, Inc.: income tax expense or benefit
- Petros Pharmaceuticals, Inc.: net property, plant and equipment
- Petros Pharmaceuticals, Inc.: share-based compensation expense
- Petros Pharmaceuticals, Inc.: operating income or loss
- Petros Pharmaceuticals, Inc.: current assets
- Petros Pharmaceuticals, Inc.: current liabilities
- Petros Pharmaceuticals, Inc.: current accounts payable
- Petros Pharmaceuticals, Inc.: net finite-lived intangible assets
- Petros Pharmaceuticals, Inc.: net current accounts receivable
- Petros Pharmaceuticals, Inc.: operating expenses
- Petros Pharmaceuticals, Inc.: net inventory
- Petros Pharmaceuticals, Inc.: gross profit
- Petros Pharmaceuticals, Inc.: selling, general and administrative expense
- Petros Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Petros Pharmaceuticals, Inc. / CIK 0001815903
- Captured
- 2026-09-19T11:21:34.055Z
- SEC response SHA-256
ce09757d7cf519fba34350164d20de41c934904fb0775c7180c184a51b39c633
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001815903.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))